Phase 2 Study of Inhaled Lipid Cisplatin in Pulmonary Recurrent Osteosarcoma
Status:
Completed
Trial end date:
2018-11-01
Target enrollment:
Participant gender:
Summary
To establish whether treatment with Inhaled Lipid Cisplatin (ILC) is effective in
delaying/preventing pulmonary relapse in osteosarcoma patients in complete surgical remission
following one or two prior pulmonary relapses.